米托胍腙(Mitoguazone) - 药物靶点：SAMDC_专利_临床

概要

基本信息

药物类型

小分子化药

别名

MGBG、Me-GAG、Methyl-G

+ [10]

靶点

SAMDC

作用机制

SAMDC抑制剂(S-腺苷甲硫氨酸脱羧酶-1抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病+ [3]

在研适应症-

非在研适应症

获得性免疫缺陷综合征非霍奇金淋巴瘤非小细胞肺癌+ [1]

原研机构

National Cancer Institute

在研机构-

非在研机构

Sanofi

National Cancer InstitutePathologica

+ [1]

最高研发阶段终止申请上市

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构

分子式C5H12N8

InChIKeyMXWHMTNPTTVWDM-UHFFFAOYSA-N

CAS号459-86-9

关联

3

项与米托胍腙相关的临床试验

NCT00002348 / Completed临床2期

Phase II Evaluation of Mitoguazone Dihydrochloride in Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma Associated With Acquired Immunodeficiency Syndrome

To estimate the response rate, response duration, clinical benefit, and toxicity of mitoguazone dihydrochloride (MGBG) in patients with AIDS-related refractory or relapsing non-Hodgkin's lymphoma (NHL).

开始日期-

申办/合作机构

Genzyme Corp.

NCT05587088 / Not yet recruiting临床1/2期IIT

Evaluation of the Safety and Efficacy of Esperanza Extract (Petiveria Alliacea) in Patients With Metastatic Gastrointestinal Tumors and Acute Leukemia

This is a phase Ib/II clinical study that has two phases. In phase Ib, the safety evaluation of the extract of Petiveria alliacea (Esperanza) will be carried out in patients with metastatic gastrointestinal tumors (colon, pancreas, stomach, and biliary tract) and patients with newly diagnosed and relapsed acute leukemia. In phase IIb, the safety will continue to be evaluated, and the efficacy of the Esperanza extract will be explored in combination with chemotherapy in patients with metastatic gastrointestinal tumors (colon, pancreas, stomach, and biliary tract) with newly diagnosed acute leukemias and relapses.

开始日期2022-12-15

申办/合作机构

Hospital Universitario San Ignacio

[+1]

NCT00920153 / Terminated临床3期IIT

Study Characterizing the Impact of Different Therapeutic Strategies on Event Occurrence at 2 Years, 5 Years, 10 Years, and 15 Years, According to Prognostic Groups in Patients With Hodgkin Lymphoma

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving drugs in different combinations may kill more cancer cells. It is not yet know which treatment regimen is more effective in treating Hodgkin lymphoma.
PURPOSE: This phase III trial is studying three different therapy regimens to compare how well they work in treating patients with previously untreated Hodgkin lymphoma.

开始日期2008-05-01

申办/合作机构-

100 项与米托胍腙相关的临床结果

登录后查看更多信息

100 项与米托胍腙相关的转化医学

登录后查看更多信息

100 项与米托胍腙相关的专利（医药）

登录后查看更多信息

391

项与米托胍腙相关的文献（医药）

2024-07-01·Biomedical Materials

Odontogenic and anti-inflammatory effects of magnesium-doped bioactive glass in vital pulp therapy

Article

作者: Chen, Xiaofeng ; Liu, Cong ; Yan, Xin ; Zhong, Yewen ; Li, Xiangdong ; Mai, Sui

AbstractThis study aimed to investigate the effects of magnesium-doped bioactive glass (Mg-BG) on the mineralization, odontogenesis, and anti-inflammatory abilities of human dental pulp stem cells (hDPSCs). Mg-BG powders with different Mg concentrations were successfully synthesized via the sol-gel method and evaluated using x-ray diffraction, Fourier-transform infrared spectroscopy, scanning electron microscopy, and transmission electron microscopy. Apatite formation was observed on the surfaces of the materials after soaking in simulated body fluid. hDPSCs were cultured with Mg-BG powder extracts in vitro, and no evident cytotoxicity was observed. Mg-BG induced alkaline phosphatase (ALP) expression and mineralization of hDPSCs and upregulated the expression of odontogenic genes, including those encoding dentin sialophosphoprotein, dentin matrix protein 1, ALP, osteocalcin, and runt-related transcription factor 2. Moreover, Mg-BG substantially suppressed the secretion of inflammatory cytokines (interleukin [IL]-4, IL-6, IL-8, and tumor necrosis factor-alpha). Collectively, the results of this study suggest that Mg-BG has excellent in vitro bioactivity and is a potential material for vital pulp therapy of inflamed pulps.

2024-03-01·European Journal of Clinical Microbiology & Infectious Diseases

A multicenter evaluation of the QIAstat-Dx meningitis-encephalitis syndromic test kit as compared to the conventional diagnostic microbiology workflow

Article

作者: van Bussel, Mario J A W M ; Claas, Eric C J ; Groot, Jelle ; van Aarle, Yvette ; Boers, Stefan A ; Smit, Louise F E ; van Sorge, Nina M ; Wessels, Els ; van Houdt, Robin

AbstractPurposeRapid diagnosis and treatment of infectious meningitis and encephalitis (ME) is critical to minimize morbidity and mortality. Recently, Qiagen introduced the CE-IVD QIAstat-Dx ME panel (QS-ME) for syndromic diagnostic testing of meningitis and encephalitis. Some data on the performance of the QS-ME in comparison to the BioFire FilmArray ME panel are available. In this study, the performance of the QS-ME is compared to the current diagnostic workflow in two academic medical centers in the Netherlands.MethodsA total of 110 cerebrospinal fluid samples were retrospectively tested with the QS-ME. The results obtained were compared to the results of laboratory-developed real-time PCR assays (LDTs), IS-pro, bacterial culture, and cryptococcal antigen (CrAg) testing. In addition, the accuracy of the QS-ME was also investigated using an external quality assessment (EQA) panel consisting of ten samples.ResultsFour of the 110 samples tested failed to produce a valid QS-ME result. In the remaining 106 samples, the QS-ME detected 53/53 viral targets, 38/40 bacterial targets, and 7/13 Cryptococcus neoformans targets. The discrepant bacterial results consisted of two samples that were previously tested positive for Listeria monocytogenes (CT 35.8) and Streptococcus pneumoniae (CT 40), respectively. The QS-ME detected one additional result, consisting of a varicella-zoster virus signal (CT 35.9), in a sample in which both techniques detected Streptococcus pyogenes. Finally, 100% concordance was achieved in testing a blinded bacterial ME EQA panel.ConclusionThe QS-ME is a relevant addition to the syndromic testing landscape to assist in diagnosing infectious ME.

2024-01-01·Chemosphere

Methyl jasmonate reduces cadmium toxicity by enhancing phenol and flavonoid metabolism and activating the antioxidant defense system in pigeon pea (Cajanus cajan)

Article

作者: Singh, Anil Kumar ; Sirhindi, Geetika ; Kaushik, Shruti ; Ranjan, Alok

Cadmium (Cd) is absorbed by plant roots from soil along with essential nutrients and affects plant growth and productivity. Methyl jasmonate (Me-JA) play important roles to mitigate Cd toxicity in plants. We have investigated the role of Me-JA to ameliorate Cd toxicity in Pigeon pea (Cajanus cajan). Plant root growth, biomass, cellular antioxidant defense system and expression of key regulatory genes in molecular and signaling process have been analyzed. Two Cajanus cajan varieties AL-882 and PAU-881 were grown at 25 °C, 16/8h light/dark conditions in three biological replicates at 5 mM Cd concentration, three concentration of Me-JA (0, 10 nM, 100 nM) and two concentrations in combination of Me-JA + Cd (10 nM Me-JA +5 mM Cd, 100 nM Me-JA +5 mM Cd). The seedlings were exposed to Cd stress consequently plants showed decrease in primary root growth (60.71%, in AL-882 and 8.33%, in PAU-881), shoot and root biomass and antioxidant enzymes activities. Me-JA treatment resulted in increased primary root growth (63.64%, in AL-882) and overall plant biomass. Oxidative stress generated due to Cd stress was counter balanced by Me-JA treatment. Me-JA reduced H₂O₂ free radicals formation and enhanced antioxidant enzyme activities and phenolic content in stressed seedlings. Me-JA treatment increased expression of CALM, IP3, CDPK2, MPKs (involved in calcium and kinase signaling pathways) and reduced expression of metal transporters (IRT1 and HMA3) genes. This reduction in metal transporters gene expression is a probable reason for low toxicity effect of Cd in root after Me-JA treatment which has potential implications in reducing the risk of Cd in the food chain.

100 项与米托胍腙相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D07258	米托胍腙	L01XX16	DB12967

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
获得性免疫缺陷综合征	申请上市	美国	Genzyme Corp.	2001-08-31
非霍奇金淋巴瘤	申请上市	-	Pathologica	-
非霍奇金淋巴瘤	申请上市	-	National Cancer Institute	-
非霍奇金淋巴瘤	申请上市	-	Sanofi	-
非霍奇金淋巴瘤	申请上市	美国	-	-
非霍奇金淋巴瘤	申请上市	-	Sanofi	-
非霍奇金淋巴瘤	申请上市	-	National Cancer Institute	-
非小细胞肺癌	申请上市	美国	-	-
非霍奇金淋巴瘤	临床2期	美国	-	-
非霍奇金淋巴瘤	临床2期	-	Pathologica	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ASCO2005	N/A	-	-	MGBG (Methionine poor medium)	鏇憲壓蓋衊淵膚繭觸繭(膚構壓築餘齋遞製夢網) = 範廠憲遞膚築製願鏇繭鏇鏇鹽蓋夢遞範獵鹹製 (窪鏇窪鑰遞遞積製範範 ) 更多	-	2005-06-01
				Methionine restriction + MGBG	鏇憲壓蓋衊淵膚繭觸繭(膚構壓築餘齋遞製夢網) = 鬱顧獵觸製壓鬱鹽廠鏇鏇鏇鹽蓋夢遞範獵鹹製 (窪鏇窪鑰遞遞積製範範 ) 更多